Raymond James Initiates Coverage On MapLight Therapeutics with Strong Buy Rating, Announces Price Target of $46

Benzinga Newsdesk www.benzinga.com Positive 89.4%

Neg 0% Neu 0% Pos 89.4%

Raymond James analyst Tiago Fauth initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Strong Buy rating and announces Price Target of $46.